High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal-Reference-Cited by-同舟云学术

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal

Published:2014-03 Issue:3 Volume:24 Page:480-487
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Bartenstein Peter¹,Calabuig Elisa Caballero²,Maini Carlo Ludovico³,Mazzarotto Renzo⁴,Muros de Fuentes M. Angustias⁵,Petrich Thorsten⁶,Rodrigues Fernando José Cravo⁷,Vallejo Casas Juan Antonio⁸,Vianello Federica⁹,Basso Michela⁹,Balaguer Marcelino Gómez¹⁰,Haug Alexander¹,Monari Fabio⁴,Vaňó Raquel Sánchez²,Sciuto Rosa³,Magner James¹¹

Affiliation:

1. Department of Nuclear Medicine, University of Munich, Munich, Germany.

2. Department of Nuclear Medicine, University Hospital Dr. Peset, Valencia, Spain.

3. Division of Nuclear Medicine, Regina Elena National Cancer Institute, Rome, Italy.

4. Hematology-Oncology Department, Radiotherapy Section, S. Orsola-Malpighi Hospital, Bologna, Italy.

5. Nuclear Medicine Department, Virgen de las Nieves University Hospital, Granada, Spain.

6. Department of Nuclear Medicine, Hannover University School of Medicine, Hannover, Germany.

7. Endocrinology Service, Portuguese Institute of Oncology of Coimbra Francisco Gentil, Coimbra, Portugal.

8. Nuclear Medicine Service, University Hospital Reina Sofía de Córdoba, Córdoba, Andalucia, Spain.

9. Department of Radiotherapy, Institute of Oncology Veneto-IRCCS, Padua, Italy.

10. Department of Endocrinology, University Hospital Dr. Peset, Valencia, Spain.

11. Global Medical Affairs, Endocrinology, Genzyme, Cambridge, Massachusetts.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2013.0157

Reference14 articles.

1. Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma

2. A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer

3. A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with Recombinant Human Thyrotropin Compared with Thyroid Hormone Withdrawal

4. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer;Clinical Nuclear Medicine;2024-01-19

2. Ablation rates and long term outcome following low dose radioiodine for differentiated thyroid cancer in the West of Scotland: a retrospective analysis;Endocrine Practice;2024-01

3. Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer;Seminars in Nuclear Medicine;2023-07

4. Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK;Clinical Oncology;2023-01

5. Diagnosis and treatment of thyroid cancer in adult patients — Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosłych — Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022];Endokrynologia Polska;2022-04-27